Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
On May 22, 2026, the Food and Drug Administration granted approval for datopotamab deruxtecan-dlnk, marketed as Datroway by Daiichi Sankyo, Inc. This approval is specifically for adult patients who have unresectable or metastatic triple-negative breast cancer (TNBC) and are not suitable candidates for PD-1/PD-L1 inhibitor therapy. (1)
(1) AACR FDA Approval Alert 2026/22/05
…